CYCLOSPORIN A (SANDIMMUN NEORAL) IN THERAPY FOR PSORIASIS AND PSORIATIC ARTHRITIS
The involvement of immune mechanisms in the pathogenesis of psoriatic arthritis (PA) is noted to give grounds to use immunoactive compounds (disease- modifying agents - basic anti-inflammatory drugs -BAIDs), such as cyclosporin A (CsA), in this disease. The data available in the literature permit a...
Main Author: | Yulia Leonodovna Korsakova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2010-09-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/307 |
Similar Items
-
Retrospective analysis of cyclosporine A (sandimmun neoral) efficacy and safety in patients with juvenile idiopathic arthritis
by: S O Salugina, et al.
Published: (2004-08-01) -
Psoriasis and psoriatic arthritis: Topical issues
by: Yulia Leonidovna Korsakova
Published: (2012-09-01) -
Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01) -
Modern pharmacotherapy of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2019-03-01) -
ENTHESITIS AND PSORIATIC ONYCHOPATHY AS A FACTOR FOR PREDICTION OF PSORIATIC ARTHRITIS IN PSORIASIS
by: Tatyana G. Sidorcika, et al.
Published: (2018-04-01)